Novo Nordisk files for FDA approval for CagriSema, the first once weekly combination of GLP1 and amylin analogues Based on the early promising data for injectable cagrilintide semaglutide combination for #obesity #T2D @novonordisk move to test an oral GLP 1 Amylin Amycretin peptide in healthy PPL with overweight and #obesity in P1 Novo Nordisk takes a hit as CagriSema underperforms in weight loss Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet